C3 and fatty liver disease: ASP dysfunction or dysfunction of transport pathways will reduce the uptake of FFAs by adipocytes, increase the flow of FFAs to the liver, and eventually lead to hypertriglyceridemia, lipid metabolism disorder and liver steatosis (19).